Chronic obstructive pulmonary disease as a risk factor for lung cancer

World Journal of Clinical Oncology

Volumn 5, Issue 4, 2014, Pages 660-666

  Takiguchi, Yuichi ^a   Sekine, Ikuo ^a   Iwasawa, Shunichiro ^a   Kurimoto, Ryota ^a   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Airflow limitation; Arcinogenesis; Cancer screening; Chronic obstructive pulmonary disease; Computed tomography screening; Early intervention; Inflammation; Lung cancer

Indexed keywords

EID: 84929408572     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i4.660     Document Type: Article

References (60)

1. World health organization fact sheets. Fact sheet N°297 Reviewed January 2013. Available from: URL: http://www. who.int/mediacentre/factsheets/fs297/en/
2. Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD). Global initiative for chronic obstructive lung disease, 2013
3. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-1692 [PMID: 12740290 DOI: 10.1378/chest.123.5.1684]
4. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-532 [PMID: 16611654 DOI: 10.1183/09031936.06.00124605]
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442 [PMID: 17132052 DOI: 10.1371/journal.pmed.0030442]
6. Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011; 81: 265-284 [PMID: 21430413 DOI: 10.1159/000324601]
7. Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med 2008; 14: 1023-1024 [PMID: 18841139 DOI: 10.1038/nm1008-1023]
8. Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794-2800 [PMID: 9493663 DOI: 10.1183/09031936.97.10122794]
9. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012 [PMID: 14999112 DOI: 10.1056/NEJMoa021322]
10. Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58: 100-105 [PMID: 12554887 DOI: 10.1136/thorax.58.2.100]
11. Górecka D, Gorzelak K, Sliwiñski P, Tobiasz M, Zieliñski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674-679 [PMID: 9337824 DOI: 10.1136/thx.52.8.674]
12. Keistinen T, Tuuponen T, Kivelä SL. Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years. Respir Med 1998; 92: 568-572 [PMID: 9692124 DOI: 10.1016/S0954-6111(98)90310-9]
13. Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953 [PMID: 10379018 DOI: 10.1056/NEJM199906243402503]
14. Vilkman S, Keistinen T, Tuuponen T, Kivelä SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 1997; 64: 281-284 [PMID: 9257363 DOI: 10.1159/000196687]
15. Zieliñski J. Circumstances of death in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1998; 53: 324-330 [PMID: 9785820 DOI:]
16. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239 [PMID: 15710956 DOI: 10.7326/0003-4819-142-4-200502150-00005]
17. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986; 105: 503-507 [PMID: 3752756 DOI: 10.7326/0003-4819-105-4-503]
18. Kuller LH, Ockene J, Meilahn E, Svendsen KH. Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Epidemiol 1990; 132: 265-274 [PMID: 2372006]
19. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007; 176: 285-290 [PMID: 17478615 DOI: 10.1164/rccm.200612-1792OC]
20. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005; 60: 570-575 [PMID: 15994265 DOI: 10.1136/thx.2004.037135]
21. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409 [PMID: 21714641 DOI: 10.1056/NEJMoa1102873]
22. Field JK, Hansell DM, Duffy SW, Baldwin DR. CT screening for lung cancer: countdown to implementation. Lancet Oncol 2013; 14: e591-e600 [PMID: 24275132 DOI: 10.1016/S1470-2045(13)70293-6]
23. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol 1982; 33: 379-387 [PMID: 7083738 DOI: 10.1016/S0009-9260(82)80301-2]
24. de Torres JP, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, Pueyo JC, Villanueva A, Lozano MD, Montes U, Montuenga L, Zulueta JJ. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 2007; 132: 1932-1938 [PMID: 18079226 DOI: 10.1378/chest.07-1490]
25. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, Wilson J, Leader JK, Siegfried JM, Shapiro SD, Sciurba FC. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 2008; 178: 738-744 [PMID: 18565949 DOI: 10.1164/rccm.200803-435OC]
26. Mizuno S, Takiguchi Y, Fujikawa A, Motoori K, Tada Y, Kurosu K, Sekine Y, Yanagawa N, Hiroshima K, Muraoka K, Mitsushima T, Niki N, Tanabe N, Tatsumi K, Kuriyama T. Chronic obstructive pulmonary disease and interstitial lung disease in patients with lung cancer. Respirology 2009; 14: 377-383 [PMID: 19192220 DOI: 10.1111/j.1440-1843.2008.01477.x]
27. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest 2010; 138: 1295-1302 [PMID: 20348193 DOI: 10.1378/chest.09-2567]
28. Li Y, Swensen SJ, Karabekmez LG, Marks RS, Stoddard SM, Jiang R, Worra JB, Zhang F, Midthun DE, de Andrade M, Song Y, Yang P. Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. Cancer Prev Res (Phila) 2011; 4: 43-50 [PMID: 21119049 DOI: 10.1158/1940-6207.CAPR-10-0151]
29. Wilson DO, Leader JK, Fuhrman CR, Reilly JJ, Sciurba FC, Weissfeld JL. Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the pittsburgh lung screening study. J Thorac Oncol 2011; 6: 1200-1205 [PMID: 21610523 DOI: 10.1097/JTO.0b013e318219aa93]
30. Zurawska JH, Jen R, Lam S, Coxson HO, Leipsic J, Sin DD. What to do when a smoker's CT scan is "normal"?: Implications for lung cancer screening. Chest 2012; 141: 1147-1152 [PMID: 22553261 DOI: 10.1378/chest.11-1863]
31. Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology 2011; 16: 1047-1055 [PMID: 21749550 DOI: 10.1111/j.1440-1843.2011.02019.x]
32. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-648 [PMID: 15286730 DOI: 10.1038/nri1415]
33. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-837 [PMID: 19269363 DOI: 10.1016/j.cell.2009.02.024]
34. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability- an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228 [PMID: 20177397 DOI: 10.1038/nrm2858]
35. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 712-719 [PMID: 17185647 DOI: 10.1164/rccm.200608-1125OC]
36. Kratz JR, Yagui-Beltrán A, Jablons DM. Cancer stem cells in lung tumorigenesis. Ann Thorac Surg 2010; 89: S2090-S2095 [PMID: 20493987 DOI: 10.1016/j.athoracsur.2010.03.038]
37. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835 [PMID: 15960971 DOI: 10.1016/j.cell.2005.03.032]
38. Kim CF. Paving the road for lung stem cell biology: bronchioalveolar stem cells and other putative distal lung stem cells. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1092-L1098 [PMID: 17693488 DOI: 10.1152/ajplung.00015.2007]
39. Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 2004; 5: 182-190 [PMID: 15003202 DOI: 10.1016/S1470-2045(04)01414-7]
40. Topic AS, Jelic-Ivanovic ZD, Spasojevic-Kalimanovska VV, Spasic SM. Association of moderate alpha-1 antitrypsin deficiency with lung cancer in the Serbian population. Arch Med Res 2006; 37: 866-870 [PMID: 16971227 DOI: 10.1016/j.arcmed.2006.05.006]
41. Yang P, Bamlet WR, Sun Z, Ebbert JO, Aubry MC, Krowka MJ, Taylor WR, Marks RS, Deschamps C, Swensen SJ, Wieben ED, Cunningham JM, Melton LJ, de Andrade M. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 2005; 128: 445-452 [PMID: 16002971 DOI: 10.1378/chest.128.1.445]
42. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE, Marks RS, de Andrade M. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008; 168: 1097-1103 [PMID: 18504338 DOI: 10.1001/archinte.168.10.1097]
43. El-Akawi ZJ, Nusier MK, Zoughool FE. Relationship between alpha-1 antitrypsin deficient genotypes S and Z and lung cancer in Jordanian lung cancer patients. Saudi Med J 2006; 27: 181-184 [PMID: 16501672]
44. Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus AM, Castegnaro M, Geneste O, Camoirano A, Saracci R, Giuntini C. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: a case-control study on lung cancer patients. Mutat Res 1991; 250: 103-114 [PMID: 1944327 DOI: 10.1016/0027-5107(91)90167-M]
45. Georgiadis P, Demopoulos NA, Topinka J, Stephanou G, Stoikidou M, Bekyrou M, Katsouyianni K, Sram R, Autrup H, Kyrtopoulos SA. Impact of phase I or phase II enzyme polymorphisms on lymphocyte DNA adducts in subjects exposed to urban air pollution and environmental tobacco smoke. Toxicol Lett 2004; 149: 269-280 [PMID: 15093273 DOI: 10.1016/j.toxlet.2003.12.038]
46. Helmig S, Hadzaad B, Döhrel J, Schneider J. Influence of the Cyp1B1 L432V gene polymorphism and exposure to tobacco smoke on Cyp1B1 mRNA expression in human leukocytes. Drug Metab Dispos 2009; 37: 1490-1495 [PMID: 19349377 DOI: 10.1124/dmd.109.027060]
47. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 2006; 17: 89-99 [PMID: 16357600 DOI: 10.1097/01.ede.0000187627.70026.23]
48. Mota P, Moura DS, Vale MG, Coimbra H, Carvalho L, Regateiro F. CYP1A1 m1 and m2 polymorphisms: genetic susceptibility to lung cancer. Rev Port Pneumol 2010; 16: 89-98 [PMID: 20054510]
49. Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR, Schwartz AG. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26: 2207-2212 [PMID: 16051642 DOI: 10.1093/carcin/bgi191]
50. Park HY, Churg A, Wright JL, Li Y, Tam S, Man SF, Tashkin D, Wise RA, Connett JE, Sin DD. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1413-1419 [PMID: 24245748 DOI: 10.1164/rccm.201305-0892OC]
51. Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martinez FD. Serum concentrations of club cell secretory protein (clara) and cancer mortality in adults: A population-based, prospective cohort study. Lancet Respir Med 2013; 1: 779-785 [PMID: 24461757 DOI: 10.1016/S2213-2600(13)70220-0]
52. Sekine Y, Yamada Y, Chiyo M, Iwata T, Nakajima T, Yasufuku K, Suzuki M, Fujisawa T. Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection. Ann Thorac Surg 2007; 84: 946-950 [PMID: 17720404 DOI: 10.1016/j.athoracsur.2007.04.038]
53. Zhai R, Yu X, Shafer A, Wain JC, Christiani DC. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest 2014; 145: 346-353 [PMID: 24008835 DOI: 10.1378/chest.13-1176]
54. Minegishi Y, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, Kudoh S, Gemma A. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 2009; 48: 665-672 [PMID: 19420811 DOI: 10.2169/internalmedicine. 48.1650]
55. Gemma A. Drug-induced interstitial lung disease (DILD) in molecular targeted therapy. Int J Clin Oncol 2012; 17: 533 [PMID: 23152006 DOI: 10.1007/s10147-012-0495-4]
56. Raviv S, Hawkins KA, DeCamp MM, Kalhan R. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. Am J Respir Crit Care Med 2011; 183: 1138-1146 [PMID: 21177883 DOI: 10.1164/rccm.201008-1274CI]
57. Kobayashi S, Suzuki S, Niikawa H, Sugawara T, Yanai M. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology 2009; 14: 675-679 [PMID: 19476597 DOI: 10.1111/j.1440-1843.2009.01543.x]
58. Fujikawa A, Takiguchi Y, Mizuno S, Uruma T, Suzuki K, Nagao K, Niijima M, Edo H, Hino M, Kuriyama T. Lung cancer screening-comparison of computed tomography and X-ray. Lung Cancer 2008; 61: 195-201 [PMID: 18242764 DOI: 10.1016/j.lungcan.2007.12.010]
59. Sekine Y, Katsura H, Koh E, Hiroshima K, Fujisawa T. Early detection of COPD is important for lung cancer surveillance. Eur Respir J 2012; 39: 1230-1240 [PMID: 22088970 DOI: 10.1183/09031936.00126011]
60. Sekine Y, Fujisawa T, Suzuki K, Tsutatani S, Kubota K, Ikegami H, Isobe Y, Nakamura M, Takiguchi Y, Tatsumi K. Detection of chronic obstructive pulmonary disease in community- based annual lung cancer screening: Chiba Chronic Obstructive Pulmonary Disease Lung Cancer Screening Study Group. Respirology 2014; 19: 98-104 [PMID: 24033868 DOI: 10.1111/resp.12179]